213 related articles for article (PubMed ID: 19672841)
1. Aspirin increases mortality in diabetic patients without cardiovascular disease: a Swedish record linkage study.
Welin L; Wilhelmsen L; Björnberg A; Odén A
Pharmacoepidemiol Drug Saf; 2009 Dec; 18(12):1143-9. PubMed ID: 19672841
[TBL] [Abstract][Full Text] [Related]
2. Use of antiplatelet therapy in a diabetic outpatient service of a large urban public hospital.
Bruno A; Grassi G; Dani F; Degiovanni M; Maghenzani G; Pagano G
Nutr Metab Cardiovasc Dis; 2005 Feb; 15(1):42-6. PubMed ID: 15871850
[TBL] [Abstract][Full Text] [Related]
3. A comparison of aspirin and clopidogrel with or without proton pump inhibitors for the secondary prevention of cardiovascular events in patients at high risk for gastrointestinal bleeding.
Hsiao FY; Tsai YW; Huang WF; Wen YW; Chen PF; Chang PY; Kuo KN
Clin Ther; 2009 Sep; 31(9):2038-47. PubMed ID: 19843493
[TBL] [Abstract][Full Text] [Related]
4. Update on aspirin in the treatment and prevention of cardiovascular disease.
Hennekens CH
Am J Manag Care; 2002 Dec; 8(22 Suppl):S691-700. PubMed ID: 12512736
[TBL] [Abstract][Full Text] [Related]
5. Aspirin and primary cardiovascular prevention. Uncertain balance between benefits and risks.
Prescrire Int; 2010 Nov; 19(110):258-61. PubMed ID: 21284360
[TBL] [Abstract][Full Text] [Related]
6. Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis.
Zhang C; Sun A; Zhang P; Wu C; Zhang S; Fu M; Wang K; Zou Y; Ge J
Diabetes Res Clin Pract; 2010 Feb; 87(2):211-8. PubMed ID: 19853947
[TBL] [Abstract][Full Text] [Related]
7. [Use of aspirin in diabetic patients].
Türkoğlu S; Abaci A
Anadolu Kardiyol Derg; 2007 Dec; 7 Suppl 2():5-8. PubMed ID: 18160360
[TBL] [Abstract][Full Text] [Related]
8. [Aspirin therapy for cardiovascular prevention in the diabetic patient: what have we learned from the evidence?].
Legrand DA; Scheen AJ
Rev Med Suisse; 2006 Aug; 2(76):1904-8. PubMed ID: 16972540
[TBL] [Abstract][Full Text] [Related]
9. Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis.
Berger JS; Brown DL; Becker RC
Am J Med; 2008 Jan; 121(1):43-9. PubMed ID: 18187072
[TBL] [Abstract][Full Text] [Related]
10. Application of U.S. guidelines in other countries: aspirin for the primary prevention of cardiovascular events in Japan.
Morimoto T; Fukui T; Lee TH; Matsui K
Am J Med; 2004 Oct; 117(7):459-68. PubMed ID: 15464702
[TBL] [Abstract][Full Text] [Related]
11. Low-dose aspirin for primary prevention of cardiovascular disease.
Bredie SJ; Wollersheim H; Verheugt FW; Thien T
Semin Vasc Med; 2003 May; 3(2):177-84. PubMed ID: 15199480
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial).
Dasgupta A; Steinhubl SR; Bhatt DL; Berger PB; Shao M; Mak KH; Fox KA; Montalescot G; Weber MA; Haffner SM; Dimas AP; Steg PG; Topol EJ;
Am J Cardiol; 2009 May; 103(10):1359-63. PubMed ID: 19427428
[TBL] [Abstract][Full Text] [Related]
13. Aspirin and gastrointestinal toxicity.
Törüner M
Anadolu Kardiyol Derg; 2007 Dec; 7 Suppl 2():27-30. PubMed ID: 18160364
[TBL] [Abstract][Full Text] [Related]
14. A case-control study of the association between polymorphisms of the endothelial nitric oxide synthase and glycoprotein IIIa genes and upper gastrointestinal bleeding in users of low-dose aspirin.
Piazuelo E; Fuentes J; García-González MA; Jiménez P; Lanas A
Clin Ther; 2008 Jan; 30(1):121-30. PubMed ID: 18343248
[TBL] [Abstract][Full Text] [Related]
15. An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial.
Wang TH; Bhatt DL; Fox KA; Steinhubl SR; Brennan DM; Hacke W; Mak KH; Pearson TA; Boden WE; Steg PG; Flather MD; Montalescot G; Topol EJ;
Eur Heart J; 2007 Sep; 28(18):2200-7. PubMed ID: 17673448
[TBL] [Abstract][Full Text] [Related]
16. [The role of aspirin in the primary prevention of cardiovascular disease].
Rodondi N; Cornuz J
Rev Med Suisse; 2006 Mar; 2(56):646-51. PubMed ID: 16597054
[TBL] [Abstract][Full Text] [Related]
17. Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses.
Hennekens CH; Sacks FM; Tonkin A; Jukema JW; Byington RP; Pitt B; Berry DA; Berry SM; Ford NF; Walker AJ; Natarajan K; Sheng-Lin C; Fiedorek FT; Belder R
Arch Intern Med; 2004 Jan; 164(1):40-4. PubMed ID: 14718320
[TBL] [Abstract][Full Text] [Related]
18. [Aspirin in cardiovascular prevention: does the approach differ by gender?].
Temizhan A
Anadolu Kardiyol Derg; 2007 Dec; 7 Suppl 2():2-4. PubMed ID: 18160359
[TBL] [Abstract][Full Text] [Related]
19. [Acetylsalicylic acid in patients with diabetes mellitus: can be used for secondary but not primary prevention of cardiovascular events].
Klomp CM; ten Cate H; Stehouwer CD; Schaper NC
Ned Tijdschr Geneeskd; 2009; 153():A109. PubMed ID: 19785798
[TBL] [Abstract][Full Text] [Related]
20. [Acetylsalicylic acid for the primary prevention of cardiovascular disease in diabetic patients].
de Lange DW; Fiets WE; Banga JD
Ned Tijdschr Geneeskd; 2004 Jul; 148(30):1481-5. PubMed ID: 15481570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
